IP Library › Granted Patent US 10,017,565

Granted Patent B2

US 10,017,565 · App. 15/250,151 · Granted Jul 10, 2018

Modulators and methods of use

Inventors: Scott J. Dylla (Emerald Hills, CA); Orit Foord (Foster City, CA); Robert A. Stull (Alameda, CA); Wade C. Anderson (Fairfield, CA); Saiyou Ohshima (Cupertino, CA)

Assignee: AbbVie Stemcentrx LLC

C07K16/18 A61K39/3955 A61K39/39558 A61K47/6825 A61K47/6849 A61K47/6851 C07K16/2896 C07K16/30 A61K2039/505 C07K2317/24 C07K2317/33 C07K2317/34 C07K2317/56 C07K2317/73 C07K2317/76 C07K2317/77 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,017,565
App. No.: 15/250,151
Granted: Jul 10, 2018
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.

Claims (99)

1. A method of reducing the frequency of tumor initiating cells in a subject in need thereof comprising administering an isolated anti-CD46 antibody or immunoreactive fragment thereof, wherein the antibody or immunoreactive fragment thereof is selected from the group consisting of:

a) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 15 for CDR-H1, residues 50-65 of SEQ ID NO: 15 for CDR-H2, and residues 95-102 of SEQ ID NO: 15 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 17 for CDR-L1, residues 50-56 of SEQ ID NO: 17 for CDR-L2 and residues 89-97 of SEQ ID NO: 17 for CDR-L3, wherein the residues are numbered according to Kabat;

b) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 19 for CDR-H1, residues 50-65 of SEQ ID NO: 19 for CDR-H2, and residues 95-102 of SEQ ID NO: 19 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 21 for CDR-L1, residues 50-56 of SEQ ID NO: 21 for CDR-L2 and residues 89-97 of SEQ ID NO: 21 for CDR-L3, wherein the residues are numbered according to Kabat;

c) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 23 for CDR-H1, residues 50-65 of SEQ ID NO: 23 for CDR-H2, and residues 95-102 of SEQ ID NO: 23 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 25 for CDR-L1, residues 50-56 of SEQ ID NO: 25 for CDR-L2 and residues 89-97 of SEQ ID NO: 25 for CDR-L3, wherein the residues are numbered according to Kabat;

d) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 27 for CDR-H1, residues 50-65 of SEQ ID NO: 27 for CDR-H2, and residues 95-102 of SEQ ID NO: 27 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 29 for CDR-L1, residues 50-56 of SEQ ID NO: 29 for CDR-L2 and residues 89-97 of SEQ ID NO: 29 for CDR-L3, wherein the residues are numbered according to Kabat;

e) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of the polypeptide encoded by the polynucleotide set forth as SEQ ID NO: 30 for CDR-H1, residues 50-65 of the polypeptide encoded by the polynucleotide set forth as SEQ ID NO: 30 for CDR-H2, and residues 95-102 of the polypeptide encoded by the polynucleotide set forth as SEQ ID NO: 30 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 33 for CDR-L1, residues 50-56 of SEQ ID NO: 33 for CDR-L2 and residues 89-97 of SEQ ID NO: 33 for CDR-L3, wherein the residues are numbered according to Kabat;

f) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 35 for CDR-H1, residues 50-65 of SEQ ID NO: 35 for CDR-H2, and residues 95-102 of SEQ ID NO: 35 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 37 for CDR-L1, residues 50-56 of SEQ ID NO: 37 for CDR-L2 and residues 89-97 of SEQ ID NO: 37 for CDR-L3, wherein the residues are numbered according to Kabat;

g) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 39 for CDR-H1, residues 50-65 of SEQ ID NO: 39 for CDR-H2, and residues 95-102 of SEQ ID NO: 39 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 41 for CDR-L1, residues 50-56 of SEQ ID NO: 41 for CDR-L2 and residues 89-97 of SEQ ID NO: 41 for CDR-L3, wherein the residues are numbered according to Kabat;

h) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 43 for CDR-H1, residues 50-65 of SEQ ID NO: 43 for CDR-H2, and residues 95-102 of SEQ ID NO: 43 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 45 for CDR-L1, residues 50-56 of SEQ ID NO: 45 for CDR-L2 and residues 89-97 of SEQ ID NO: 45 for CDR-L3, wherein the residues are numbered according to Kabat;

i) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 47 for CDR-H1, residues 50-65 of SEQ ID NO: 47 for CDR-H2, and residues 95-102 of SEQ ID NO: 47 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 49 for CDR-L1, residues 50-56 of SEQ ID NO: 49 for CDR-L2 and residues 89-97 of SEQ ID NO: 49 for CDR-L3, wherein the residues are numbered according to Kabat;

j) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 51 for CDR-H1, residues 50-65 of SEQ ID NO: 51 for CDR-H2, and residues 95-102 of SEQ ID NO: 51 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 53 for CDR-L1, residues 50-56 of SEQ ID NO: 53 for CDR-L2 and residues 89-97 of SEQ ID NO: 53 for CDR-L3, wherein the residues are numbered according to Kabat;

k) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 55 for CDR-H1, residues 50-65 of SEQ ID NO: 55 for CDR-H2, and residues 95-102 of SEQ ID NO: 55 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 57 for CDR-L1, residues 50-56 of SEQ ID NO: 57 for CDR-L2 and residues 89-97 of SEQ ID NO: 57 for CDR-L3, wherein the residues are numbered according to Kabat;

l) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 59 for CDR-H1, residues 50-65 of SEQ ID NO: 59 for CDR-H2, and residues 95-102 of SEQ ID NO: 59 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 61 for CDR-L1, residues 50-56 of SEQ ID NO: 61 for CDR-L2 and residues 89-97 of SEQ ID NO: 61 for CDR-L3, wherein the residues are numbered according to Kabat;

m) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 63 for CDR-H1, residues 50-65 of SEQ ID NO: 63 for CDR-H2, and residues 95-102 of SEQ ID NO: 63 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 65 for CDR-L1, residues 50-56 of SEQ ID NO: 65 for CDR-L2 and residues 89-97 of SEQ ID NO: 65 for CDR-L3, wherein the residues are numbered according to Kabat;

n) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 67 for CDR-H1, residues 50-65 of SEQ ID NO: 67 for CDR-H2, and residues 95-102 of SEQ ID NO: 67 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 69 for CDR-L1, residues 50-56 of SEQ ID NO: 69 for CDR-L2 and residues 89-97 of SEQ ID NO: 69 for CDR-L3, wherein the residues are numbered according to Kabat;

o) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 71 for CDR-H1, residues 50-65 of SEQ ID NO: 71 for CDR-H2, and residues 95-102 of SEQ ID NO: 71 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 73 for CDR-L1, residues 50-56 of SEQ ID NO: 73 for CDR-L2 and residues 89-97 of SEQ ID NO: 73 for CDR-L3, wherein the residues are numbered according to Kabat;

p) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 75 for CDR-H1, residues 50-65 of SEQ ID NO: 75 for CDR-H2, and residues 95-102 of SEQ ID NO: 75 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 77 for CDR-L1, residues 50-56 of SEQ ID NO: 77 for CDR-L2 and residues 89-97 of SEQ ID NO: 77 for CDR-L3, wherein the residues are numbered according to Kabat;

q) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 79 for CDR-H1, residues 50-65 of SEQ ID NO: 79 for CDR-H2, and residues 95-102 of SEQ ID NO: 79 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 81 for CDR-L1, residues 50-56 of SEQ ID NO: 81 for CDR-L2 and residues 89-97 of SEQ ID NO: 81 for CDR-L3, wherein the residues are numbered according to Kabat;

r) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 83 for CDR-H1, residues 50-65 of SEQ ID NO: 83 for CDR-H2, and residues 95-102 of SEQ ID NO: 83 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 85 for CDR-L1, residues 50-56 of SEQ ID NO: 85 for CDR-L2 and residues 89-97 of SEQ ID NO: 85 for CDR-L3, wherein the residues are numbered according to Kabat;

s) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 199 for CDR-H1, residues 50-65 of SEQ ID NO: 199 for CDR-H2, and residues 95-102 of SEQ ID NO: 199 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 201 for CDR-L1, residues 50-56 of SEQ ID NO: 201 for CDR-L2 and residues 89-97 of SEQ ID NO: 201 for CDR-L3, wherein the residues are numbered according to Kabat; and

t) an antibody comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 203 for CDR-H1, residues 50-65 of SEQ ID NO: 203 for CDR-H2, and residues 95-102 of SEQ ID NO: 203 for CDR-H3, and comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 205 for CDR-L1, residues 50-56 of SEQ ID NO: 205 for CDR-L2 and residues 89-97 of SEQ ID NO: 205 for CDR-L3, wherein the residues are numbered according to Kabat.

2. The method of claim 1 , wherein the antibody or immunoreactive fragment thereof is selected from the group consisting of:

a) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 15, and comprising a light chain variable region set forth as SEQ ID NO: 17;

b) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 18, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 20;

c) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 23, and comprising a light chain variable region set forth as SEQ ID NO: 25;

d) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 27, and comprising a light chain variable region set forth as SEQ ID NO: 29;

e) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 30, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 32;

f) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 35, and comprising a light chain variable region set forth as SEQ ID NO: 37;

g) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 39, and comprising a light chain variable region set forth as SEQ ID NO: 41;

h) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 42, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 44;

i) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 46, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 48;

j) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 51, and comprising a light chain variable region set forth as SEQ ID NO: 53;

k) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 55, and comprising a light chain variable region set forth as SEQ ID NO: 57;

l) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 59, and comprising a light chain variable region set forth as SEQ ID NO: 61;

m) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 63, and comprising a light chain variable region set forth as SEQ ID NO: 65;

n) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 67, and comprising a light chain variable region set forth as SEQ ID NO: 69;

o) an antibody comprising a heavy chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 70, and comprising a light chain variable region encoded by the polynucleotide set forth as set forth as SEQ ID NO: 72;

p) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 75, and comprising a light chain variable region set forth as SEQ ID NO: 77;

q) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 79, and comprising a light chain variable region set forth as SEQ ID NO: 81; and

r) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 83, and comprising a light chain variable region set forth as SEQ ID NO: 85;

s) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 199, and comprising a light chain variable region set forth as SEQ ID NO: 201; and

t) an antibody comprising a heavy chain variable region set forth as SEQ ID NO: 203, and comprising a light chain variable region set forth as SEQ ID NO: 205.

3. The method of claim 1 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof is selected from the group consisting of monoclonal antibodies, chimeric antibodies, CDR-grafted antibodies, and humanized antibodies.

4. The method of claim 1 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof is conjugated to a cytotoxic agent and optionally comprises a pharmaceutically acceptable carrier.

5. The method of claim 2 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof is conjugated to a cytotoxic agent and optionally comprises a pharmaceutically acceptable carrier.

6. The method of claim 5 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof comprises a heavy chain variable region set forth as SEQ ID NO: 199, and comprising a light chain variable region set forth as SEQ ID NO: 201.

7. The method of claim 5 , wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof comprises a heavy chain variable region set forth as SEQ ID NO: 203, and comprising a light chain variable region set forth as SEQ ID NO: 205.

8. The method of claim 1 , wherein the reduction in frequency of tumor initiating cells is determined using in vitro or in vivo limiting dilution analysis.

9. The method of claim 8 , wherein the reduction in frequency of tumor initiating cells is determined using analysis of tumor cell surface markers known to enrich for tumor initiating cells.

10. The method according to claim 8 , wherein the reduction in frequency is determined using in vivo limiting dilution analysis comprising transplant of live human tumor cells into immunocompromised mice.

11. A method of treating a cancer in a subject comprising administering an isolated anti-CD46 antibody or immunoreactive fragment, wherein the isolated anti-CD46 antibody or immunoreactive fragment thereof is selected from the group consisting of:

12. The method of claim 11 , wherein the antibody or immunoreactive fragment thereof is selected from the group consisting of: